Diffuse large B-cell lymphoma+2
RecruitingStudy of loncastuximab tesirine and epcoritamab combination treatment for patients with relapsed or refractory diffuse large B-cell lymphoma
Study of loncastuximab tesirine and epcoritamab combination treatment for patients with relapsed or refractory diffuse large B-cell lymphoma
- Disease:Diffuse large B-cell lymphomaFollicular lymphoma+1
- Substances:EpcoritamabLoncastuximab Tesirine
Italy- Participants:18–64 years · 65+ years
- Substances:Epcoritamab
- Sponsor:Universitaet Muenster









